Claims
- 1. A compound selected from the group consisting of 6H-dibenz[b,e][1,4]oxathiepins having the structural formulae: ##STR24## wherein Z is a member selected from the group consisting of thio, sulfinyl, and sulfonyl;
- R.sub.2 and R.sub.3 are the same or different and are members selected from the group consisting of hydrogen, halogen, nitro, loweralkyl, amino, N-loweralkylamino, N,N-diloweralkylamino, loweralkanoyl, hydroxy, loweralkoxy, loweralkylthio, trifluoromethylthio, loweralkylsulfinyl, loweralkylsulfonyl, and trifluoromethyl; and
- R.sub.1 is a member selected from the group consisting of 5-tetrazolyl and 5-tetrazolylmethyl; and the pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 having the name;
- 9-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11, 11-dioxide;
- 9-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11-oxide;
- 2-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin;
- 2-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11-oxide;
- 2-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11,11-dioxide;
- 9-(1H-Tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin;
- 9-[(1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin;
- 9-[1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin-11-oxide;
- 9[1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin-11,11-dioxide;
- 2-[(1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin;
- 2-[(1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin-11oxide;
- 2-[(1H-Tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin-11,11-dioxide.
- 3. A compound of claim 1, wherein Z is thio.
- 4. A compound of claim 1, wherein Z is thio and R.sub.1 is 5-tetrazolyl.
- 5. A compound of claim 1, wherein Z is thio; R.sub.2 is selected from hydrogen, amino, nitro or fluoro; R.sub.3 is hydrogen; and R.sub.1 is 5-tetrazolyl.
- 6. A compound of claim 5, wherein R.sub.2 is hydrogen and R.sub.1 is 5-tetrazolyl.
- 7. The compound of claim 6, which is 2-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin.
- 8. The compound of claim 6, which is 9-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin.
- 9. A compound of claim 1, wherein Z is sulfinyl; R.sub.2 is selected from hydrogen, amino, nitro or fluoro; R.sub.3 is hydrogen, and R.sub.1 is 5-tetrazolyl.
- 10. A compound of claim 9, wherein R.sub.2 is hydrogen and R.sub.1 is 5-tetrazolyl.
- 11. The compound of claim 10, which is 2-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11-oxide.
- 12. The compound of claim 10, which is 9-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11-oxide.
- 13. A compound of claim 1, wherein Z is sulfonyl; R.sub.2 is selected from hydrogen, amino, nitro or fluoro; R.sub.3 is hydrogen; and R.sub.1 is 5-tetrazolyl.
- 14. A compound of claim 13, wherein R.sub.2 is hydrogen and R.sub.1 is 5-tetrazolyl.
- 15. The compound of claim 14, which is 2-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11,11-dioxide.
- 16. The compound of claim 14, which is 9-(1H-tetrazol-5-yl)-6H-dibenz[b,e][1,4]oxathiepin-11,11-dioxide.
- 17. A compound of claim 1, wherein Z is thio; R.sub.2 is selected from hydrogen, amino, nitro or fluoro; R.sub.3 is hydrogen; and R.sub.1 is 5-tetrazolylmethyl.
- 18. A compound of claim 17, wherein R.sub.2 is hydrogen and R.sub.1 is 5-tetrazolylmethyl.
- 19. The compound of claim 18, which is 2-[(1H-tetrazol-5-yl)methyl]-6H-dibenz[b,e][1,4]oxathiepin.
- 20. A compound of claim 1, wherein Z is sulfinyl; R.sub.2 is selected from hydrogen, amino, nitro or fluoro; R.sub.3 is hydrogen; and R.sub.1 is 5-tetrazolylmethyl.
- 21. A pharmaceutical composition for the treatment and control of asthma which comprises a pharmaceutically acceptable carrier and an anti-asthmatic effective amount of a compound of claim 1.
- 22. A method for the treatment and control of asthma which comprises administering to humans or warm-blooded animals in need of such treatment an anti-asthmatic effective amount of a compound of claim 1.
CROSS REFERENCE TO RELATED APPLICATIONS
This is a division of application Ser. No. 536,104 filed Oct. 8, 1983 and now U.S. Pat. No. 4,582,842 and this application is a continuation-in-part of copending application Ser. No. 238,097 filed Feb. 25, 1981, abandoned which was a continuation of Ser. No. 930,103, filed Aug. 1, 1978, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4091108 |
Batchelor et al. |
May 1978 |
|
4103015 |
Hodson et al. |
Jul 1978 |
|
4582842 |
Cragoe et al. |
Apr 1986 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
536104 |
Oct 1983 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
930103 |
Aug 1978 |
|